Arcturus Therapeutics Balances Pipeline Progress With Cash Strain

Arcturus Therapeutics ((ARCT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Arcturus Therapeutics’ latest earnings call struck a cautiously balanced tone, pairing notable scientific and regulatory wins with clear commercial and financial pressure. Management emphasized new validation for its self‑amplifying mRNA platform and meaningful cost cuts, yet acknowledged that shrinking revenues, finite cash and limited clinical data keep the long‑term investment case far from de‑risked.

Costave wins U.K. approval but faces commercial questions

The highlight was January’s U.K. MHRA approval of Costave, Arcturus’ self‑amplifying mRNA COVID‑19 vaccine for adults 18 and over, marking an important regulatory milestone for the platform. While this validates the sa‑mRNA technology and opens a commercial door, management underscored that pricing, uptake and especially U.S. regulatory clarity remain unresolved near‑term hurdles.

ARCT‑2304 shows durable H5N1 immunity in Phase I

BARDA‑funded A/H5N1 candidate ARCT‑2304 completed a Phase I study in 212 younger and 80 older adults, with eight‑month follow‑up demonstrating durable immune responses across 1.5, 5 and 12 µg doses. No material safety issues emerged and cell‑mediated immunity signals were observed, supporting the broader STARR sa‑mRNA platform as Arcturus positions itself for future pandemic‑preparedness opportunities.

ARCT‑032 moves into longer Phase II testing for CF

Cystic fibrosis program ARCT‑032 is advancing from an initial four‑week dosing regimen into a planned 12‑week Phase II trial starting in the first half of 2026, enrolling up to roughly 20 Class I patients across U.S. and international sites. Early cohorts showed no safety issues at 15 mg in four patients, and at 10 mg, four of six subjects demonstrated reduced mucus plugs after 28 days, hinting at efficacy.

ARCT‑810 prepares for pivotal path in OTC deficiency

For OTC deficiency, Arcturus is steering ARCT‑810 toward pivotal development aimed at both late‑onset adults and severely affected young children. Type C regulatory meetings scheduled for the first half of 2026 are expected to clarify trial design, endpoints and sequencing across adult and pediatric indications, which will be crucial for shaping timelines and ultimate commercial scope.

Dose flexibility supports cost and efficacy trade‑offs

The company underscored its ability to adjust dosing on key programs, opting for 10 mg in an upcoming ARCT‑032 cohort while retaining capacity to move to 15 mg and citing prior experience up to 27 mg. This range gives Arcturus room to tune efficacy exploration against manufacturing economics, since lower doses reduce cost of goods and could improve margins if products reach market.

Sharper cost controls extend cash runway to 2028

Management highlighted aggressive expense discipline, with annual R&D cut by $83.0M and G&A reduced by $6.7M, while quarterly R&D fell by $19.3M. These measures, alongside a strategic refocus of the pipeline, have pushed the company’s cash runway into the second quarter of 2028, buying time to execute on clinical milestones without immediate financing.

Revenues slide sharply as CSL activity slows

Despite operational progress, Arcturus posted a steep revenue decline, with annual revenue down $70.3M and quarterly revenue off $15.6M year over year. The main driver was lower activity and fewer development milestones under the CSL collaboration as Costave shifted toward commercialization, underscoring the company’s heavy reliance on partnership economics.

Lower R&D spend reflects maturing programs, slower throughput

The $83.0M annual reduction in R&D spending largely reflected reduced manufacturing and clinical costs as LUNAR‑COV19 moved into its commercial phase and other trials wrapped up. While investors may welcome lower cash burn, management acknowledged that leaner spending could also translate into slower development throughput in certain areas of the pipeline.

Cash down to $232.8M, leaving a finite runway

Cash, cash equivalents and restricted cash declined to $232.8M at year‑end 2025 from $293.9M a year earlier, a drop of $61.1M or about 20.8%. Although the runway extension to mid‑2028 offers breathing room, the absolute cash level remains a key constraint, implying that successful execution and potential additional partnerships or funding will be needed over time.

CSL partnership and U.S. market remain key unknowns

Arcturus tied much of its revenue pressure to reduced CSL collaboration milestones and noted ongoing discussions with the partner regarding next steps. Management further pointed to regulatory and administrative challenges around Costave in the U.S., leaving a cloud over the vaccine’s commercial trajectory and introducing an added layer of uncertainty for investors.

Early‑stage clinical data still need scale and duration

Across several programs, management stressed that efficacy evidence is still early and based on small patient cohorts, such as ARCT‑032’s six‑subject signal at 10 mg and pending 15 mg data. The pivotal strategy for ARCT‑810 also hinges on upcoming regulator feedback, meaning larger, longer studies will be required before the therapeutic value of these assets can be firmly established.

Legal overhang adds another layer of risk

The company also flagged a lawsuit filed in late 2025 against AbbVie and Capstone Therapeutics as an unresolved issue. While details were limited on the call, Arcturus acknowledged that the legal process could introduce operational or financial uncertainty depending on how the case ultimately unfolds.

Guidance highlights clinical milestones and financial discipline

Looking ahead, management reaffirmed that the 12‑week Phase II ARCT‑032 trial should start dosing in the first half of 2026, with up to 20 Class I CF patients evaluated via lung function, imaging and quality of life endpoints. They also reiterated H1 2026 Type C meetings for ARCT‑810, recent U.K. approval for Costave, durable ARCT‑2304 Phase I H5N1 data, and a cash runway into Q2 2028 supported by ongoing G&A reductions.

Arcturus’ earnings call painted a company at a strategic crossroads, with high‑value scientific assets and fresh regulatory wins offset by tightening finances and commercial ambiguity. For investors, the story hinges on whether upcoming CF and OTC data, combined with clearer CSL and regulatory outcomes, can convert today’s platform promise into durable revenue and shareholder value.